The functional role of Ly9 on NK cells is unknown; however, a Ly9-engineered CAR T cell therapy has shown beneficial anti-tumour effect in murine models by targeting CD229hi myeloma cells (70) which suggests Ly9 acts as an activating receptor. Here, LY9 is linked to neoplasm.